Tesamorelin Peptide

Tesamorelin was developed through research into GHRH peptides, building on discoveries that synthetic analogs could prolong the half-life and activity of native GHRH fragments. It was synthesized in the late 1990s and early 2000s as a stabilized peptide with improved pharmacokinetic properties, allowing for sustained endocrine pathway activation in experimental models. Research expanded into its effects on downstream signaling and systemic function, where it has remained an important tool in laboratory and preclinical studies.

CAS #: 218949-48-5
Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight: ~5136 g/mol
PubChem ID: 16137828

Tesamorelin has been studied in endocrine, signaling, and molecular models, with research highlighting its activity in somatotroph axis modulation, downstream cascades, pathway dynamics, and protein synthesis pathways. Studies also report effects on lipid pathway signaling, endocrine markers, and molecular proliferation in preclinical systems.

Key Areas of Research:

• Endocrine: Somatotroph axis, signaling, cascades
• Signaling: Lipid pathways, dynamics, markers
• Molecular: Proliferation, remodeling, protein synthesis

Together, these findings suggest broad experimental potential for Tesamorelin across endocrine, signaling, and molecular pathways. By modulating somatotroph axis activity and influencing downstream cascades and protein synthesis processes, Tesamorelin provides a versatile research platform for exploring molecular remodeling, pathway characterization, and endocrine biology in laboratory settings.